Skip to Content

Oliver Bogler, Ph.D.

Present Title & Affiliation

Primary Appointment

Senior Vice President, Academic Affairs, Division of Academic Affairs, Sr VP Office, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Neurosurgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Dean, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Neuro-Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Baylor College of Medicine, Houston, TX
Director, Brain Tumor Research Center, Laboratory Research Sub-committee, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor, Department of Neuro-Oncology - Research, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Bogler studied Natural Sciences at Cambridge University graduating in 1988, and then moved to the laboratory of Dr. Mark Noble, Ludwig Institute for Cancer Research, University College Branch in London, UK for his PhD, which he completed in 1991. Following a post-doc at the Salk Institute in Developmental Neurobiology, he rejoined the Ludwig Institute, working with Dr. Webster Cavenee, Director of the San Diego Branch. His first faculty appointment in 1997, was in the Departments of Anatomy and Neurosurgery at Virginia Commonwealth University in Richmond. In 2000 he moved to the Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit and was promoted to Associate Professor in 2002. In 2005 Dr. Bogler joined the Department of Neurosurgery and the Brain Tumor Center at the UT MD Anderson Cancer Center as Director of Basic Research, and was promoted to Professor in 2009. His research is focused on EGFR signaling in glioma and novel platinum compounds. In July 2010 Dr. Bogler accepted the position of Vice President for Global Academic Programs in MD Anderson’s Center for Global Oncology, where he manages academic relationships external to MD Anderson’s main campus in Houston. In September 2011 he was appointed Senior Vice President for Academic Affairs and oversees 16 departments that deliver support for the academic and education activities at MD Anderson.

Office Address

The University of Texas MD Anderson Cancer Center
1400 Pressler Street
Unit Number: 1422
Houston, TX 77030
Room Number: FCT6.5012
Phone: 713-792-0873
Fax: 713-745-4277

Education & Training

Degree-Granting Education

1991 Ludwig Institute for Cancer Research, University College Branch, London, London, United Kingdom, PHD, Cancer Research
1988 University of Cambridge, Cambridge, United Kingdom, BA, First Class Honors, Natural Sciences

Postgraduate Training

1/1993-1/1997 Research Fellowship, Brain Tumor Biology, Ludwig Institute for Cancer Research, San Diego, CA, Webster Cavenee, Ph.D.
1/1991-12/1992 Research Fellowship, Molecular Neurobiology, Salk Institute for Biological Studies, La Jolla, CA, Dr. Greg Lemke


Academic Appointments

Vice President, Global Academic Programs, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2010-10/2012
Associate Professor, Department of Pathology, School of Medicine, Wayne State University, Detroit, MI, 2/2004-3/2005
Senior Staff Scientist, Department of Neurosurgery, Hermlin Brain Tumor Center, Detroit, MI, 5/2000-6/2002

Administrative Appointments/Responsibilities

Director, Basic Research, Department of Neurosurgery,, University of Texas MD Anderson Cancer Center, Houston, TX, 3/2005-6/2010

Other Appointments/Responsibilities

AACR Science Education Committee Member, American Association of Cancer Research, Philadelphia, PA, 11/2008-present

Institutional Committee Activities

Member, GSBS Student Affairs Committee, 10/2009-9/2012
Executive Committee Member, Faculty Senate, 6/2007-6/2010

Honors and Awards

1997 Society for Neuro-Oncology Research Excellence Award sponsored by the, American Brain Tumor Association

Professional Memberships

American Association for Cancer Research
Member Science Education Committee, 11/2008-present
Member, 1994-present
Society for NeuroOncology
Member, 1997-2011
Chairman of the Communications/Publications, 1997-2008

Selected Publications

Peer-Reviewed Original Research Articles

1. Latha K, Li M, Chumbalkar V, Gururaj A, Hwang Y, Dakeng S, Sawaya R, Aldape K, Cavenee WK, Bogler O, Furnari FB. Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter. Int J Cancer 132(3):509-20, 2/2013. e-Pub 7/2012. PMID: 22729867.
2. Doucette TA, Kong LY, Yang Y, Ferguson SD, Yang J, Wei J, Qiao W, Fuller GN, Bhat KP, Aldape K, Priebe W, Bögler O, Heimberger AB, Rao G. Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro Oncol 14(9):1136-45, 9/2012. e-Pub 6/2012. PMID: 22753228.
3. Hwang Y, Chumbalkar V, Latha K, Bogler O. Forced dimerization increases the activity of deltaEGFR/EGFRvIII and enhances its oncogenicity. Mol Cancer Res 9(9):1199-208, 9/2011. e-Pub 7/2011. PMCID: PMC3175255.
4. Chumbalkar V, Latha K, Hwang Y, Maywald R, Hawley L, Sawaya R, Diao L, Baggerly K, Cavenee WK, Furnari FB, Bogler O. Analysis of Phosphotyrosine Signaling in Glioblastoma Identifies STAT5 as a Novel Downstream Target of ΔEGFR. J Proteome Res 10(3):1343-52, 3/2011. e-Pub 2/2011. PMCID: PMC3049961.
5. Gwak HS, Shingu T, Chumbalkar V, Hwang YH, DeJournett R, Latha K, Koul D, Alfred Yung WK, Powis G, Farrell NP, Bögler O. Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma. Int J Cancer 128(4):787-96, 2/2011. e-Pub 4/2010. PMCID: PMC2990813.
6. Staquicini FI, Ozawa MG, Moya CA, Driessen WH, Barbu EM, Nishimori H, Soghomonyan S, Flores LG, Liang X, Paolillo V, Alauddin MM, Basilion JP, Furnari FB, Bogler O, Lang FF, Aldape KD, Fuller GN, Hook M, Gelovani JG, Sidman RL, Cavenee WK, Pasqualini R, Arap W. Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. J Clin Invest 121(1):161-73, 1/2011. e-Pub 12/2010. PMCID: PMC3007161.
7. Shingu T, Chumbalkar VC, Gwak HS, Fujiwara K, Kondo S, Farrell NP, Bogler O. The polynuclear platinum BBR3610 induces G2/M arrest and autophagy early and apoptosis late in glioma cells. Neuro Oncol 12(12):1269-77, 12/2010. e-Pub 8/2010. PMCID: PMC3018945.
8. Shimokawa N, Haglund K, Holter SM, Grabbe C, Kirkin V, Koibuchi N, Schultz C, Rozman J, Hoeller D, Qiu CH, Londono MB, Ikezawa J, Jedlicka P, Stein B, Schwarzacher SW, Wolfer DP, Ehrhardt N, Heuchel R, Nezis I, Brech A, Schmidt MH, Fuchs H, Gailus-Durner V, Klingenspor M, Bogler O, Wurst W, Deller T, de Angelis MH, Dikic I. CIN85 regulates dopamine receptor endocytosis and governs behaviour in mice. EMBO J 29(14):2421-32, 7/2010. e-Pub 6/2010. PMCID: PMC2910270.
9. Shingu T, Fujiwara K, Bogler O, Akiyama Y, Moritake K, Shinojima N, Tamada Y, Yokoyama T, Kondo S. Inhibition of autophagy at a late stage enhances imatinib-induced cytotoxicity in human malignant glioma cells. Int J Cancer 124(5):1060-71, 3/2009. PMID: 19048625.
10. The Cancer Genome Atlas (TCGA) Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061-8, 2008.
11. Dejournett R, Kobayashi R, Pan S, Su C, Etkin LD, Clark RB, Bogler O, Kuang J. Phosphorylation of proline-rich domain of XP95 modulates XP95 interaction with partner proteins. J Biochem 401:521-531, 2007. PMID: 16978157.
12. Billecke C, Finniss S, Tahash L, Miller C, Mikkelsen T, Farrell NP, Bogler O,. Polynuclear platinum anticancer drugs are more potent than cisplatin and induce cell cycle arrest in glioma. Neuro-Oncology 8:215-226, 2006. PMID: 16723633.
13. Schmidt MH, Dikic I, Bogler O. Src phosphorylation of Alix/AIP1 modulates its interaction with binding partners and antagonizes its activities. J Biol Chem 280(5):3414-25, 2/2005. PMID: 15557335.
14. Schmidt MH, Hoeller D, Yu J, Furnari FB, Cavenee WK, Dikic I, Bogler O. Alix/AIP1 antagonizes epidermal growth factor receptor downregulation by the Cbl-SETA/CIN85 complex. Mol Cell Biol 24(20):8981-93, 10/2004. PMID: 15456872.
15. Peterson EJ, Bogler O, Taylor SM. p53-mediated repression of DNA methyltransferase 1 expression by specific DNA binding. Cancer Res 63(20):6579-82, 10/2003. PMID: 14583449.
16. Schmidt MH, Chen B, Randazzo LM, Bogler O. SETA/CIN85/Ruk and its binding partner AIP1 associate with diverse cytoskeletal elements, including FAKs, and modulate cell adhesion. J Cell Sci 116(Pt 14):2845-55, 7/2003. PMID: 12771190.
17. Schmidt MH, Furnari FB, Cavenee WK, Bogler O. Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. Proc Natl Acad Sci U S A 100(11):6505-10, 5/2003. PMID: 12734385.
18. Chen B, Borinstein SC, Gillis J, Sykes VW, Bogler O. The glioma-associated protein SETA interacts with AIP1/Alix and ALG-2 and modulates apoptosis in astrocytes. J Biol Chem 275(25):19275-81, 6/2000. PMID: 10858458.
19. Bogler O, Furnari FB, Kindler-Roehrborn A, Sykes VW, Yung R, Huang HJ, Cavenee WK. SETA: a novel SH3 domain-containing adapter molecule associated with malignancy in astrocytes. Neuro-oncol 2(1):6-15, 2000. PMID: 11302255.
20. Bogler O, Nagane M, Gillis J, Huang HJ, Cavenee WK. Malignant transformation of p53-deficient astrocytes is modulated by environmental cues in vitro. Cell Growth Differ 10(2):73-86, 2/1999. PMID: 10074901.
21. Bogler O, Huang HJ, Cavenee WK. Loss of wild-type p53 bestows a growth advantage on primary cortical astrocytes and facilitates their in vitro transformation. Cancer Res 55(13):2746-51, 7/1995. PMID: 7796398.
22. Bogler O, Noble M. Measurement of time in oligodendrocyte-type-2 astrocyte (O-2A) progenitors is a cellular process distinct from differentiation or division. Dev Biol 162(2):525-38, 4/1994. PMID: 8150211.
23. Bogler O, Wren D, Barnett SC, Land H, Noble M. Cooperation between two growth factors promotes extended self-renewal and inhibits differentiation of oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells. Proc Natl Acad Sci U S A 87(16):6368-72, 8/1990. PMID: 2201028.

Grant & Contract Support

Title: Polynuclear platinums in targeted and combination glioma therapy
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2008 - 8/31/2013
Title: CURE Supplement
Funding Source: Cancer Center Support Grant (CCSG)
Role: Co-Investigator
Principal Investigator: Ronald A. DePinho
Duration: 7/1/2008 - 6/30/2013
Title: SPORE in Brain Cancer
Funding Source: NIH/NCI
Role: Co-Leader Project 2
Duration: 3/1/2008 - 2/28/2013
Title: Investigating the Biological Role of the Glioma Associated Gene SETA
Funding Source: James S. McDonnell Foundation
Role: Principal Investigator
Principal Investigator: Principal Investigator
Duration: 10/1/1998 - 12/31/2001

Last updated: 4/23/2014